What is HC Wainwright’s Forecast for CADL FY2030 Earnings?

Candel Therapeutics, Inc. (NASDAQ:CADL) – Analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Candel Therapeutics in a report released on Thursday, March 12th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of $2.91 for the year. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.47) per share.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.30).

Other equities analysts have also issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Wednesday, January 21st. Zacks Research raised shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Stephens restated an “overweight” rating and issued a $15.00 price target on shares of Candel Therapeutics in a report on Monday, December 8th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $25.00 price target on shares of Candel Therapeutics in a research report on Friday. Finally, Citigroup decreased their price objective on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.00.

Candel Therapeutics Price Performance

CADL stock opened at $4.99 on Monday. The stock has a 50-day moving average price of $5.59 and a two-hundred day moving average price of $5.42. Candel Therapeutics has a 12-month low of $4.25 and a 12-month high of $9.08. The company has a current ratio of 13.49, a quick ratio of 13.49 and a debt-to-equity ratio of 0.91. The company has a market cap of $273.95 million, a PE ratio of -7.03 and a beta of -0.90.

Hedge Funds Weigh In On Candel Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CADL. Acorn Capital Advisors LLC boosted its holdings in Candel Therapeutics by 19.9% in the 2nd quarter. Acorn Capital Advisors LLC now owns 2,580,517 shares of the company’s stock worth $13,057,000 after acquiring an additional 428,265 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Candel Therapeutics during the second quarter valued at approximately $126,000. XTX Topco Ltd purchased a new stake in shares of Candel Therapeutics during the second quarter valued at approximately $378,000. The Manufacturers Life Insurance Company acquired a new position in shares of Candel Therapeutics during the second quarter worth $70,000. Finally, Invesco Ltd. acquired a new position in shares of Candel Therapeutics during the first quarter worth $59,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Candel Therapeutics

In related news, Director Paul B. Manning bought 550,458 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was bought at an average price of $5.45 per share, with a total value of $2,999,996.10. Following the completion of the transaction, the director directly owned 2,763,527 shares of the company’s stock, valued at approximately $15,061,222.15. This represents a 24.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.60% of the stock is owned by insiders.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.